1. IDF21-0338 Results of Randomized Double Blind Phase III trial of FDC of Remogliflozin Etabonate and Teneligliptin in T2DM patients. (April 2022) Authors: Balamurgan, R.; Mohan, B.; Kodgule, R.; Tandon, M.; Pendse, A.; Khaladkar, K.; Sharath, R.; Katare, S.; Suryawanshi, S.; Barkate, H. Journal: Diabetes research and clinical practice Issue: Volume 186:Supplement 1(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗